Fabupharm

Fabupharm (Pty) Ltd. is a Namibian pharmaceutical manufacturer offering over 180 products, including food supplements and toiletries, aimed at enhancing health and wellness across various market segments in Africa. Fabupharm (Pty) Ltd. specializes in the manufacture of pharmaceutical products.

Founded in 1989, the company is headquartered in Otjiwarongo, Namibia. In September 2016, EOS Capital acquired a 35% minority stake in Fabupharm. The founder's history is not detailed in the available information. Fabupharm (Pty) Ltd.

specializes in the manufacture of a diverse range of pharmaceutical products, exceeding 180 in total, which encompass food supplements, toiletries, and both registered and non-registered products. These products are designed to address various health and wellness needs, aiming to improve the quality of life for consumers in Namibia and beyond. Fabupharm operates across nine distinct product categories, ensuring a comprehensive portfolio that caters to both everyday health concerns as well as specific therapeutic needs. The company targets various market segments, including individual consumers, healthcare providers, and retailers, effectively serving the broader Namibian and African markets, with an emphasis on countries such as South Africa, Botswana, Mozambique, Nigeria, Zambia, Ghana, and Mauritius.

By focusing on affordable quality, Fabupharm strives to position itself as a trusted provider of pharmaceutical solutions in these regions. Fabupharm’s revenue generation model is primarily driven through partnerships with retailers and wholesalers, as well as direct sales to consumers. The company engages with retail chains, particularly in South Africa, including established outlets like Clicks, Dischem, and PEP, facilitating a significant distribution channel for its products. Transactions typically involve bulk orders from retailers, which are complemented by targeted marketing strategies to optimize product placement and visibility in stores.

While specific pricing structures for individual products are not disclosed, the firm’s offerings include flagship products positioned at competitive price points, catering to a wide customer demographic. Overall, Fabupharm’s revenue framework is designed to enhance accessibility to their pharmaceutical products, fostering strong relationships with both consumers and distribution partners in the African market. Fabupharm is focused on expanding its product range and market reach. The company plans to design and launch new products aimed at addressing specific health needs, with anticipated releases in the upcoming 18 months.

Moreover, Fabupharm seeks to expand into additional African markets, targeting regions such as Tanzania and Kenya by 2024. The recent funding from EOS Capital will be utilized to support these new product developments and market expansion efforts, allowing the company to enhance its operations and service delivery.